William Kirby, MD
Internal Medicine · Birmingham, ALNPI 1750499844
Payments from drug & device makers
Across 1,132 payments — averaging $1999.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi Pasteur Inc.$665K
- Sanofi US Services Inc.$356K
- Eli Lilly$305K
- Janssen Research & Development, LLC$212K
- Merck$138K
- Kowa Research Institute, Inc.$133K
- plus $455K from 32 others
Across 33 payments — averaging $189.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$4K
- Sanofi US Services Inc.$2K
- Eli Lilly$256
What the payments were for
- Food & beverage$3,38997%
- Education$1163%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi Pasteur Inc. | 80 | $665,403 |
| Sanofi US Services Inc. | 385 | $355,533 |
| Eli Lilly | 30 | $305,109 |
| Janssen Research & Development, LLC | 21 | $212,188 |
| Merck | 27 | $137,555 |
| Kowa Research Institute, Inc. | 67 | $132,895 |
| Vertex | 4 | $95,400 |
| AstraZeneca | 10 | $74,037 |
| Regeneron | 31 | $69,185 |
| AbbVie | 57 | $69,012 |
| Novartis | 8 | $46,484 |
| Novo Nordisk AS | 10 | $33,692 |
| Astrazeneca UK Limited | 2 | $31,313 |
| Alnylam Pharmaceuticals Inc. | 186 | $8,424 |
| Ironwood Pharmaceuticals, Inc | 2 | $7,547 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $7,213 |
| Eli Lilly Export S.A. Puerto Rico Branch | 2 | $3,316 |
| Rhythm Pharmaceuticals, Inc. | 1 | $2,648 |
| Modernatx, Inc. | 4 | $1,310 |
| Teva Pharmaceuticals USA, Inc. | 1 | $1,300 |
| E.r. Squibb & Sons, L.L.C. | 2 | $916 |
| Novo Nordisk | 43 | $603 |
| GSK | 28 | $487 |
| Pfizer | 28 | $414 |
| Dexcom, Inc. | 22 | $403 |
| Amgen | 16 | $307 |
| Johnson & Johnson | 17 | $215 |
| Astellas Pharma US Inc | 6 | $203 |
| Abbott | 10 | $189 |
| Boehringer Ingelheim | 8 | $125 |
| Lilly USA, LLC | 6 | $96 |
| Exact Sciences | 2 | $40 |
| Radius Health, Inc. | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
| Z-medica, LLC | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$2,263,709 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 382 | $481,005 |
| MounjaroTirzepatide | 236 | $262,682 |
| EliquisApixaban | 228 | $171,155 |
| JardianceEmpagliflozin | 173 | $157,990 |
| TrulicityDulaglutide | 112 | $151,684 |
| JanuviaSitagliptin Phosphate | 90 | $86,937 |
| LinzessLinaclotide | 76 | $54,220 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $42,702 |
| MyrbetriqMirabegron | 35 | $39,091 |
| XareltoRivaroxaban | 32 | $32,471 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $29,925 |
| Breo ElliptaFluticasone/Vilanterol | 47 | $20,337 |
| FarxigaDapagliflozin Propanediol | 30 | $17,297 |
| TradjentaLinagliptin | 25 | $17,172 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $16,598 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $603 | $481,005382 claims |
| Lilly USA, LLCMounjaro, Trulicity | $96 | $414,366348 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Glyxambi | $125 | $196,904231 claims |
| PfizerEliquis | $414 | $171,155228 claims |
| MerckJanuvia, Janumet Xr, Belsomra | $137,555 | $113,360135 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $487 | $63,040109 claims |
| AbbVieLinzess | $69,012 | $54,22076 claims |
| Astellas Pharma US IncMyrbetriq | $203 | $39,09135 claims |
| Johnson & JohnsonXarelto | $215 | $32,47132 claims |
| AstraZenecaFarxiga | $74,037 | $17,29730 claims |
| NovartisEntresto | $46,484 | $14,71818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Birmingham
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Jordan VaughnBirmingham$1.6M
- Stefanie KrickBirmingham$527K
- Ryan WeldonBirmingham$458K
- Ashraf KhanBirmingham$215K
- Robert LewisBirmingham$201K
- David WynneBirmingham$180K
- Kevin RiggsBirmingham$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.